Session 8: Debate: Triplet Chemotherapy (FOLFOXIRI) + Bevacizumab vs Doublet Chemotherapy (FOLFOX/FOLFIRI) + Panitumumab for Left-sided all RAS Wild-Type Metastatic Colorectal Cancer (mCRC)

Session 8: Debate: Triplet Chemotherapy (FOLFOXIRI) + Bevacizumab vs Doublet Chemotherapy (FOLFOX/FOLFIRI) + Panitumumab for Left-sided all RAS Wild-Type Metastatic Colorectal Cancer (mCRC) - Discussion

Friday, September 29, 2023

8:45 AM - 9:00 AM ET

Moderator(s)

David H. Ilson, MD, PhD

Weill Cornell Medical College, Memorial Hospital, Memorial Sloan Kettering Cancer Center

Panelist(s)

Cathy Eng, MD, FACP, FASCO

Vanderbilt-Ingram Cancer Center
MD Anderson Cancer Center
Namrata (Neena) Vijayvergia, MD, FACP

Fox Chase Cancer Center